Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Next Generation Antimicrobial Diagnostics: Population-wide genome sequencing to deduce determinants of antibiotic resistance in Pseudomonas aeruginosa chronic lung infections.
FY 2013-14
Summary
Pseudomonas aeruginosa (PsA), a pathogen often resistant to multiple antibiotics, is the most prevalent cause of respiratory infections in adult patients with cystic fibrosis (CF). The treatment of bacterial infections, including those by PsA, is typically guided by ""culture and sensitivity"" results, whereby samples from patients are cultured nutrient rich media (i.e. in vitro) to identify pathogenic species, which are then tested for susceptibility to many antibiotics. This process can take up to three days after specimen collection, often requiring the tentative administration of broad spectrum anti-PsA antibiotics, forgoing the concerns of toxicity and selective pressures for antibiotic resistance. This approach assumes that the causative agent is largely genotypically and phenotypically uniform, and usually attributable to a single predominant pathogen, further implying that these in vitro antibiotic resistance profiles accurately reflect the resistance profile of organisms causing the infection in vivo. Indeed, PsA population studies of sputum isolates from chronically PsA infected CF patients demonstrate that there is vast phenotypic variation, including variability in antibiotic resistance profiles, even among isolates obtained from the same patient. This variability may explain why many patients fail to respond to therapy deemed appropriate based on antibiotic susceptibility testing.
Thus far, most attempts to identify the genetic determinants of antibiotic susceptibility have relied on methods that only differentiate between the presence or absence of single genes (e.g. gene-knockout studies) within single isolates, thus oversimplifying the multifaceted mechanisms of resistance acquisition in vivo. These observations taken together would suggest that chronic PsA infections should be approached with a 'microbiome' or population-based perspective. With the advent of Next Generation Sequencing (NGS) in the post-genomic era, and the progression of computational statistical methods, multiple genomes from a single patient sample can now be sequenced quickly and at a relatively low cost. This means that large-scale Multi-Genome Wide Association Studies (MGWAS) attempting to identify resistance gene mutations among a population are now feasible. Furthermore, as the availability of NGS increases, it will soon likely become a staple in the clinical diagnosis of bacterial infections allowing for more infection-specific antibiotic therapies to be developed, theoretically reducing the propagation of antibiotic resistance.
We propose to identify and characterize genetic determinants of antibiotic resistance in PsA within chronically infected CF patients using a population-based strategy. We hypothesize that the selective pressure of the repeated use of multiple antibiotics is a key driver of variation in PsA populations within the lungs of these patients. Our aims are as follows:
1) To identify genomic alterations in PsA populations associated with antibiotic resistance using Illumina-based genome sequencing from the sputum of chronically infected CF patients.
2) To further characterize genomic alterations associated with tobramycin resistance identified in Aim #1 using our library of susceptibility characterized PsA isolates by means of fitness and competition assays.
The necessary resources and methods for these aims are all in place through the CIHR CF Lung Microbiome team co-led by Dr. Guttman and Dr. Hwang. This work will help identify clinically relevant genetic correlates of antibiotic resistance in PsA infections. It should also help us better understand why eradicating chronic PsA infections is so challenging, and perhaps suggest new strategies for their management.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311873
Name
Shelton Kaleb A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Next Generation Antimicrobial Diagnostics: Population-wide genome sequencing to deduce determinants of antibiotic resistance in Pseudomonas aeruginosa chronic lung infections.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibiotics And Resistance; Bacteria; Bioinformatics; Cystic Fibrosis; Genome Wide Association Studies; Genomics; Genotype And Phenotype; Human Microbiome; Next Generation Sequencing; Pseudomonas Aeruginosa
Abstract
Pseudomonas aeruginosa (PsA), a pathogen often resistant to multiple antibiotics, is the most prevalent cause of respiratory infections in adult patients with cystic fibrosis (CF). The treatment of bacterial infections, including those by PsA, is typically guided by ""culture and sensitivity"" results, whereby samples from patients are cultured nutrient rich media (i.e. in vitro) to identify pathogenic species, which are then tested for susceptibility to many antibiotics. This process can take up to three days after specimen collection, often requiring the tentative administration of broad spectrum anti-PsA antibiotics, forgoing the concerns of toxicity and selective pressures for antibiotic resistance. This approach assumes that the causative agent is largely genotypically and phenotypically uniform, and usually attributable to a single predominant pathogen, further implying that these in vitro antibiotic resistance profiles accurately reflect the resistance profile of organisms causing the infection in vivo. Indeed, PsA population studies of sputum isolates from chronically PsA infected CF patients demonstrate that there is vast phenotypic variation, including variability in antibiotic resistance profiles, even among isolates obtained from the same patient. This variability may explain why many patients fail to respond to therapy deemed appropriate based on antibiotic susceptibility testing.
Thus far, most attempts to identify the genetic determinants of antibiotic susceptibility have relied on methods that only differentiate between the presence or absence of single genes (e.g. gene-knockout studies) within single isolates, thus oversimplifying the multifaceted mechanisms of resistance acquisition in vivo. These observations taken together would suggest that chronic PsA infections should be approached with a 'microbiome' or population-based perspective. With the advent of Next Generation Sequencing (NGS) in the post-genomic era, and the progression of computational statistical methods, multiple genomes from a single patient sample can now be sequenced quickly and at a relatively low cost. This means that large-scale Multi-Genome Wide Association Studies (MGWAS) attempting to identify resistance gene mutations among a population are now feasible. Furthermore, as the availability of NGS increases, it will soon likely become a staple in the clinical diagnosis of bacterial infections allowing for more infection-specific antibiotic therapies to be developed, theoretically reducing the propagation of antibiotic resistance.
We propose to identify and characterize genetic determinants of antibiotic resistance in PsA within chronically infected CF patients using a population-based strategy. We hypothesize that the selective pressure of the repeated use of multiple antibiotics is a key driver of variation in PsA populations within the lungs of these patients. Our aims are as follows:
1) To identify genomic alterations in PsA populations associated with antibiotic resistance using Illumina-based genome sequencing from the sputum of chronically infected CF patients.
2) To further characterize genomic alterations associated with tobramycin resistance identified in Aim #1 using our library of susceptibility characterized PsA isolates by means of fitness and competition assays.
The necessary resources and methods for these aims are all in place through the CIHR CF Lung Microbiome team co-led by Dr. Guttman and Dr. Hwang. This work will help identify clinically relevant genetic correlates of antibiotic resistance in PsA infections. It should also help us better understand why eradicating chronic PsA infections is so challenging, and perhaps suggest new strategies for their management.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shelton, Kaleb A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~